A Study of XTR004 Radiotracer in Healthy Volunteers

Sinotau Pharmaceutical Group

Status and phase: Completed; Phase 1

Conditions: Myocardial Ischemia; Coronary Artery Disease (CAD)

Treatments: Diagnostic Test: XTR004

Study type: Interventional

Funder types: Industry

Identifiers

NCT05195879

STB-XTR004-101

Details and patient eligibility

About

XTR004 is a 18F-labeled myocardial perfusion positron emission tomography tracer use to measure myocardial perfusion and myocardial blood flow. XTR004 binds to the myocytes and targets respiratory chain complex 1 in the mitochondria.This phase I study investigated the safety, biodistribution, radiation dosimetry and Pharmacokinetics of XTR004 in 10 healthy Chinese adults volunteers.

Full description

XTR004 is a 18F-labeled myocardial perfusion PET tracer, the first one developed in China by Sinotau Pharmaceutical Group. XTR004 targets and binds to the mitochondrial complex I protein. XTR004 reflects myocardial function at a molecular level. In pre-clinical studies XTR004 demonstrated high myocardial first-pass extraction and prolonged retention, allowing for early or delayed imaging. XTR004 can be clinically used to measure myocardial perfusion and myocardial blood flow. This Phase I study will be open-labeled, nonrandomized, single center study. Enrolled 10 healthy Chinese adults who meet all of the inclusion and none of the exclusion criteria. Subjects will receive 6-8 mCi of XTR004 via IV injection. Safety and tolerability will be observed. Biodistribution, pharmacokinetics, and dosimetry will be investigated.

Enrollment: 10 patients

Sex: All

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Chinese men and women are included age between 18-40 years
2. Normal vital signs and physical examination
3. No clinical abnormalities in ECG, EEG, and echocardiogram
4. No past history of cardiovascular, cerebrovascular, or gastrointestinal diseases
5. Normal or no clinical significance abnormalities in laboratory tests
6. No any other major or chronic illness
7. No presence of drug use
8. Females adopt effective medically approved contraceptive methods to prevent pregnancy for at least 6 months before the study and after the study
9. Voluntarily agree and signed written consent

Exclusion criteria

1. Previous history of cardiovascular diseases
2. A history of or physical or radiographic manifestations of any previous brain disease
3. Any previous major disease or unstable condition
4. Subjects who cannot complete XTR004 imaging as required
5. Positive HIV, hepatitis C or Treponema pallidum antibody and hepatitis B surface antigen detection
6. A history of coagulation or coagulation disorder
7. A history of liver or gastrointestinal disease or other conditions that interfere with drug absorption, distribution, excretion or metabolism as determined by the investigator
8. Previous history of cancer
9. High risk of drug allergic reaction
10. A history of alcohol or drug abuse/dependence
11. Exposure to significant occupational radiation (e.g >50 mvs/year) or exposure to radioactive substances for therapeutic or research purposes over the past 10 years
12. Scheduled surgery or other invasive interventions within one week before drug injection
13. Subjects use any drug or treatment that may interfere with the experimental data or cause serious side effects, as determined by the investigator
14. Pregnant or lactating women
15. Admitted to hospital due to illness during screening period Other conditions that investigators consider inappropriate to participate in a trial.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

XTR004

Experimental group

Description:

Single dose 6.0-8.0 mCi intravenous injection of XTR004 and investigation of XTR004 (MPI radiotracer).

Treatment:

Diagnostic Test: XTR004